Modality
Degrader
MOA
EGFRi
Target
FcRn
Pathway
PI3K/AKT
CeliacFTDCRC
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
Mar 2017
→ Feb 2025
Phase 2Current
NCT05509066
565 pts·Celiac
2020-06→2025-02·Completed
NCT04345307
1,525 pts·FTD
2017-03→TBD·Active
2,090 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-141.1y agoPh2 Data· Celiac
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P2
Active
P2
Complet…
Catalysts
Ph2 Data
2025-02-14 · 1.1y ago
Celiac
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05509066 | Phase 2 | Celiac | Completed | 565 | DAS28 |
| NCT04345307 | Phase 2 | FTD | Active | 1525 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |